Buy or sell

Investors loved it when the generic drug firm was the subject of buyout talks. Now they’re just as pleased that Actavis is buying smaller Warner Chilcott instead. The sector is so ripe for consolidation that it’s hard to come up with any combination that investors won’t embrace.